A Self-Help Metacognitive Therapy for Cardiac Rehabilitation Patients (PATHWAY WS3)
Launched by UNIVERSITY OF MANCHESTER · Jun 24, 2019
Trial Information
Current as of August 19, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Patients who are referred to the CR pathway who meet Department of Health (DoH) and/or British Association for Cardiovascular Prevention and Rehabilitation (BACPR) CR eligibility criteria:
- • Acute coronary syndrome used for any condition brought on by sudden, reduced blood flow to the heart
- • Following revascularisation is the restoration of perfusion to a body part or organ that has suffered ischemia
- • Stable heart failure
- • Stable angina is chest pain or discomfort that most often occurs with activity or stress
- • Following implantation of cardioverter defibrillators/cardiac resynchronisation devices
- • Heart valve repair/replacement
- • Heart transplantation and ventricular assist devices
- • Adult congenital heart disease identified in adulthood
- • Other (atypical heart presentation: nausea, dizziness, lower chest discomfort, upper abdominal pressure or discomfort that feels like indigestion and upper back pain)
- • 2. A score of ≥ 8 on either the depression or anxiety subscale of the Hospital Anxiety and Depression Scale
- • 3. Minimum of 18 years old
- • 4. Competent level of English language skills
- Exclusion Criteria:
- • 1. Cognitive impairment which precludes informed consent or ability to participate
- • 2. Acute suicidality
- • 3. Active psychotic disorders (i.e., two \[or more\] of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, negative symptoms).
- • 4. Current drug/alcohol abuse (A maladaptive pattern of drinking, leading to clinically significant impairment or distress)
- • 5. Concurrent psychological intervention for emotional distress that is not part of usual care
- • 6. Antidepressant or anxiolytic medications initiated in the previous 8 weeks
- • 7. Life expectancy of less than 12 months
- • -
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bolton, , United Kingdom
Liverpool, , United Kingdom
Macclesfield, , United Kingdom
Manchester, , United Kingdom
Manchester, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials